EVALUATION OF THE DATA OF EFFECTIVENESS OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION BY THE METHOD OF INTEGRATION OF ANGIOGENESIS INHIBITORS INTO THE BACK SUBTENON SPACE ON THE VISCOUS MEDIA



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim of the research. Study of clinical efficacy of treatment of wet form of age-related macular degeneration by using the method of introduction of the inhibitor of angiogenesis into the back s ubtenon s pace on the viscous media. Material and methods of the study. The first group (main group) included 41 patients (43 eyes) with wet form of age-related macular degeneration (AMD). All patients in this group were injected in the back subtenon space 7.5-12.5 mg of an angiogenesis inhibitor on a viscous medium (1.0 ml of 2% solution of hydroxypropylmethyl cellulose). The second group (control group) consisted of 30 patients (30 eyes) with wet form of AMD, for this group a retrospective analysis of dynamics of morpho-functional indices after intravitreal injections of angiogenesis inhibitors according to standard methods (1.25 mg) was carried out. The observance time period amounted to 12 months. Results. When comparing the effectiveness of treatment, the mean best-corrected visual acuity (BCVA) improved significantly in both groups after treatment. Also, according to data of the optical coherence tomography (OCT), the mean central retinal thickness (CRT), the extent, height of pathological changes, the area of the pathological focus and the relative volume of the pathological focus were significantly reduced as a result of treatment. No significant differences were found between the groups (all p>0.05). In accordance with results of the evaluation, the effect duration at subtenon method of administrations amounted to 2-2.5 months, at intravitreal method it amounted to 1-1.5 months. The number of administrations in the 12 months of observation in the main group amounted to 2.8 injections per patient on average, and in the control group it amounted to 4.2 injections. Conclusion: Subtenon injections of the inhibitor of angiogenesis into the back subtenon space gives the positive effect in the treatment of wet form of age-related macular degeneration, and its application on viscous medium has a prolonged effect.

Full Text

Restricted Access

About the authors

R V Gaybaryan

FSBSI «Rostov State Medical University» of Ministry of healthcare of the Russian Federation

A N Epikhin

FSBSI «Rostov State Medical University» of Ministry of healthcare of the Russian Federation

U N Epikhina

FSBSI «Rostov State Medical University» of Ministry of healthcare of the Russian Federation

U F Bondarenko

FSBSI «Rostov State Medical University» of Ministry of healthcare of the Russian Federation

N A Epikhin

FSBSI «Rostov State Medical University» of Ministry of healthcare of the Russian Federation

References

  1. Жайворонок Н.С., Смолякова Г.П., Данилова Л.П., Еманова Л.П., Поваляева Д.А. Отдаленные результаты антиангиогенной терапии неоваскулярных форм возрастной макулярной дегенерации // Современные технологии в офтальмологии. 2017. No 2. С. 198-201. [Zhajvoronok N.S., Smolyakova G.P., Danilova L.P., Emanova L.P., Povalyaeva D.A. Long-term results of antiangiogenic therapy of neovascular forms of age-related macular degeneration, Sovremennye tehnologii v oftal'mologii, 2017, No 2, рр. 198-201].
  2. Solomon S.D., Lindsley K, Vedula S.S., Krzystolik M.G., НашМш B.S. Anti-vascular endothelial growth fаctоr for neovascular аgе-rеlаtеd macular degeneration // Cochrane Dаtаbаsе Syst. Яе^ 2 014. Vol. 8. 139 р.
  3. Zhao L, Grob S, Avery R, Kimura A. et al. Common variant in VEGF-A and response to anti-VEGF therapy for neovascular age-related macular degeneration // Curr. Mol. Med. 2013. Vol. 13 (6). Р. 929-934.
  4. Ventrice P, Leporini C, Aloe J.F. et al. Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases // J. Pharmacol Pharmacother. 2013. Vol. 4. P. 38-42.
  5. Sampat K.M., Garg S.J. Complications of intravitreal injections // Curr. Opin. Ophthalmol. 2010. Vol. 21, No 3. P. 178-183.
  6. Ventrice P, Leporini C, Aloe J.F., Greco E, Leuzzi G., Marrazzo G, Scorcia G.B., Bruzzichesi D, Nicola V, Scorcia V. Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases // Pharmacol Pharmacother. 2013. Vol. 4. P. 38-42.
  7. Potter M.J., Szabo S.M., Ho T. Combined photodynamic therapy and intravitreal triamcinolone for the treatment of myopic choroidal neovascularization in a 13 -year old girl // Graefe’s A rch. Clin. Exp. Ophthalmol. 2006. Vol. 244. P. 639-641.
  8. Басинский C.H., Красногорская B.H., Басинский A.C. Ме20ды введения лекарс2венных препара20в к заднему 02делу глаза // Клиническая оф2альмология. 2008. No 2. С. 54-57. [Basinskij S.N., Krasnogorskaya V.N., Basinskij A.S. Methods of administration of drugs to the posterior part of the eye, Klinicheskaya oftal'mologiya, 2008, No 2, рр. 54-57].
  9. Porter R.G., Karki S.B. Choroidal neovascularization secondary to cuticular drusen treated with intravitreal bevacizumab // Retin Cаsеs Brief. 2014. Vol. 8. No 4. P. 326-329.
  10. Menke M.N., Zinkernagel M.S. et al. Functional and anatomical outcome of еуеs with neovascular аgе-rеlаtеd macular degeneration trеаtеd with intravitreal ranibizumab following =п exit strategy regimen // Brit. J. Ophthalmol. 2014. Vol. 98, No 9. P. 1197-1200.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Gaybaryan R.V., Epikhin A.N., Epikhina U.N., Bondarenko U.F., Epikhin N.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies